UK Drug Safety Research Unit Finds Remdesivir ‘Favorable’ for COVID-19 Patients

October 7, 2020

A benefit-risk evaluation of Gilead Sciences’ remdesivir by the UK’s Drug Safety Research Unit found the antiviral’s benefit-risk profile was “favorable” for COVID-19 patients.

The research unit noted benefits including faster recovery time and reductions in the need for ventilation and supportive oxygen.

Based on the limited safety data available, it was unclear if reported adverse events – such as cardiovascular problems, multiple organ dysfunction and gastrointestinal events – were linked to the disease or the treatment, the research unit said.